Related Experiment Videos
[Liposomal amphotericin B]
1Sumitomo Pharmaceuticals Co., Ltd., Product Development Division, Tokyo, Japan.
Nihon Ishinkin Gakkai Zasshi = Japanese Journal of Medical Mycology
|November 12, 2005
Summary
Liposomal amphotericin B (AmBisome) offers effective antifungal treatment with reduced toxicity compared to conventional amphotericin B. This drug delivery system targets fungal infections, minimizing side effects like kidney damage.
Area of Science:
- Mycology
- Pharmacology
- Drug Delivery Systems
Context:
- Amphotericin B (AMPH-B) is a gold standard antifungal agent.
- AMPH-B exhibits broad-spectrum activity against Candida and Aspergillus.
- AMPH-B toxicity, particularly nephrotoxicity, limits its clinical use.
Purpose:
- To evaluate liposomal amphotericin B (AmBisome) as a safer alternative to conventional AMPH-B.
- To assess AmBisome's efficacy and toxicity profile in treating fungal infections.
Summary:
- AmBisome is a liposomal formulation of AMPH-B designed to reduce toxicity.
- It functions by targeting ergosterol in fungal membranes, leading to cell death.
- AmBisome demonstrates comparable antifungal activity to AMPH-B but with significantly reduced infusion-related toxicity and nephrotoxicity.
Impact:
- AmBisome provides an improved therapeutic option for invasive fungal infections.
- Reduced toxicity enhances patient tolerance and treatment adherence.
- Liposomal drug delivery systems offer a viable strategy for mitigating drug-induced side effects.